TICKERNERD
Menu
RIGLRIGLHealthcare · Biotechnology

RIGL Stock Forecast: Rigel Pharmaceuticals, Inc. Price Predictions for 2026-2027

Last close, 21 Aug 2026
$46
+1.41% on the day

The 5 Wall Street analysts covering Rigel Pharmaceuticals, Inc. hold a median 12-month price target of $55 — +19.9% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 79 of 100 as at 22 Aug 2026 — inside the top quartile. Here, the model and the Street point the same way.

Market cap
$857.2M
Ticker Nerd rank
79 / 100
Median analyst target
$55
Analysts covering
5
Total return, dividends reinvested
1W
+7.8%
1M
+16.7%
YTD
+7.1%
1Y
+9.3%
From 52W high
−9.9%
From 52W low
+80.4%
$25
$51
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

RIGL stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Rigel Pharmaceuticals, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026
79 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Value
98
Quality
96
Momentum
81
Issuance
77
Growth
57
Revisions
50
Size
47
Volatility
42
Accruals
13

Value (98): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.

Accruals (13): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

RIGL stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on RIGL, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$20$30$40$50$60$70$80$90Oct 25Jan 26Apr 26Jul 26RIGLHigh $85Median $55Low $43

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says5 analysts
3 Buy2 Hold0 Sell
Low $43Median $55High $85

The green dot is the last close — the median target sits +19.9% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
17 Aug 2026Piper SandlerMaintainsNeutral$40 → $49
14 Aug 2026HC Wainwright & Co.MaintainsBuy$57 → $85
2 June 2026HC Wainwright & Co.ReiteratesBuy—
2 June 2026HC Wainwright & Co.ReiteratesBuy$57
27 May 2026HC Wainwright & Co.ReiteratesBuy—
27 May 2026HC Wainwright & Co.ReiteratesBuy$57
22 May 2026HC Wainwright & Co.ReiteratesBuy—
13 May 2026CitigroupMaintainsBuy—
7 May 2026CitigroupMaintainsBuy—
5 Nov 2025Cantor FitzgeraldMaintainsNeutral—
5 Nov 2025JefferiesUpgradeBuy—
8 Oct 2025HC Wainwright & Co.ReiteratesBuy—
6 Aug 2025Cantor FitzgeraldMaintainsNeutral—
7 May 2025Cantor FitzgeraldMaintainsNeutral—
6 Mar 2025CitigroupMaintainsBuy—
5 Mar 2025B. Riley SecuritiesMaintainsNeutral—
5 Mar 2025HC Wainwright & Co.ReiteratesBuy—
23 Jan 2025HC Wainwright & Co.ReiteratesBuy—
22 Jan 2025HC Wainwright & Co.ReiteratesBuy—
14 Jan 2025HC Wainwright & Co.ReiteratesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. RIGL appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

RIGL analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
+14.7%
Analysts raising
1
Analysts cutting
1
Fundamentals

Rigel Pharmaceuticals, Inc. (RIGL) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
2.7×

Cheaper than 69% of US stocks

Price / sales
3.1×

Cheaper than 41% of US stocks

Price / book
2.0×

Cheaper than 47% of US stocks

EV / EBITDA
8.9×

Cheaper than 42% of US stocks

Growth & margins
Revenue growth (YoY)
−22.6%

Higher than 10% of US stocks

Earnings growth (YoY)
−71.0%

Higher than 6% of US stocks

Gross margin
89.2%

Higher than 96% of US stocks

Operating margin
30.0%

Higher than 87% of US stocks

Net margin
116.3%

Higher than 99% of US stocks

Returns & dividend
Return on equity
126.9%

Higher than 97% of US stocks

Return on assets
15.0%

Higher than 97% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

RIGL vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
RIGLRigel Pharmaceuticals, Inc.$857.2M
79
TBPHTheravance Biopharma, Inc.$856.6M
89
FTHFaeth Therapeutics, Inc.$824.9M
54
FDMT4D Molecular Therapeutics, Inc.$874.5M
53
ACHVAchieve Life Sciences, Inc.$820.2M
29
SGPSpyGlass Pharma, Inc.$883.2M
1
AURAAura Biosciences, Inc.$806.4M
41

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Rigel Pharmaceuticals, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest RIGL news & analysis

Rigel Announces Availability of VEPPANU™ (vepdegestrant) for Patients with ER+/HER2-, ESR1-Mutated Advanced or Metastatic Breast Cancer

PRNewsWire · 13 Aug 2026positive

Rigel Pharmaceuticals announced that VEPPANU (vepdegestrant) is now available by prescription in the U.S. for adults with ER+/HER2-, ESR1-mutated advanced or metastatic breast cancer whose disease progressed after at least one line of endocrine therapy. The drug is described as the first and only FDA-approved PROTAC.

Why it matters — This marks the commercial availability of Rigel's first-and-only FDA-approved PROTAC for a defined breast cancer patient population, expanding the company's product portfolio.

Rigel Pharmaceuticals: A Four-Drug Company With A Clinical Catalyst Ahead

Seeking Alpha · 6 Aug 2026positive

Rigel Pharmaceuticals in-licensed Veppanu, a treatment for certain breast cancer patients targeting a $1B market, with revenues expected as early as Q3'26. Q2'26 showed strong sales growth from Tavalisse and Rezlidhia, offsetting Gavreto's middling performance, while the company guides $285M–$295M in 2026 revenues excluding Veppanu upside. Upcoming R289 phase 1b data and readouts from Veppanu and Rezlidhia trials are cited as additional growth catalysts.

Why it matters — RIGL watchers would care because a newly in-licensed breast cancer drug, a multi-product portfolio, and several upcoming clinical data readouts give Rigel multiple near-term growth opportunities beyond its existing commercial products.

Rigel Pharmaceuticals: The Easy Money Has Been Made (Rating Downgrade)

Seeking Alpha · 5 Aug 2026negative

Seeking Alpha downgraded Rigel Pharmaceuticals, noting that its Q2 revenue and EPS beat, driven by TAVALISSE sales, was offset by a year-over-year decline in GAVRETO and a guidance increase that came from contract revenue rather than accelerating core product sales, with net product sales guidance unchanged. VEPPANU was described as strategically sound but only incrementally valuable after upfront payments, milestones, and high royalties.

Why it matters — A RIGL watcher would care because the item argues the company's share appreciation has already occurred and that the quality of its earnings beat is weaker than headline numbers suggest.

Rigel Pharmaceuticals, Inc. (RIGL) Q2 2026 Earnings Call Transcript

Seeking Alpha · 5 Aug 2026neutral

Seeking Alpha published the transcript of Rigel Pharmaceuticals' Q2 2026 earnings call, covering the company's quarterly results and management discussion.

Why it matters — A RIGL watcher would care because the transcript offers a direct record of management's comments on the quarter's financial performance and company outlook.

Rigel Pharmaceuticals Q2 Earnings Call Highlights

MarketBeat · 5 Aug 2026positive

Rigel Pharmaceuticals reported second-quarter 2026 total revenue of $78.7 million and net income of $17.3 million. The company also outlined plans to launch the newly licensed breast cancer therapy VEPPANU in mid-August.

Why it matters — Rigel watchers would care because the quarterly revenue and net income figures, along with the upcoming VEPPANU launch timing, indicate commercial and pipeline progress at the company.

FAQ

Frequently asked questions about RIGL stock

What is the RIGL stock price forecast for 2026-2027?

The 5 Wall Street analysts covering Rigel Pharmaceuticals, Inc. have a median 12-month price target of $55, with estimates ranging from $43 to $85. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is RIGL stock a buy right now?

Of the 5 analysts covering Rigel Pharmaceuticals, Inc., 3 rate it a Buy, 2 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Rigel Pharmaceuticals, Inc. 79 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank RIGL?

As at 22 Aug 2026, Rigel Pharmaceuticals, Inc. ranks 79 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Value (98 of 100).

Will RIGL stock go up?

No one can know that. What the data says: the median 12-month target from 5 analysts implies +19.9% from the last close, and Ticker Nerd's factor model ranks Rigel Pharmaceuticals, Inc. 79 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the RIGL stock forecast for 2030?

No analyst covering Rigel Pharmaceuticals, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for RIGL are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $43 to $85 over the next 12 months.

How has RIGL stock performed over the past year?

Rigel Pharmaceuticals, Inc. returned +9.3% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Rigel Pharmaceuticals, Inc. do?

Rigel Pharmaceuticals, Inc. is a biotechnology company focused on discovering, developing, and providing novel therapies that significantly improve the lives of patients with hematologic disorders and cancer.

What is the latest news on RIGL?

The most recent item we track (PRNewsWire, 13 Aug 2026): "Rigel Announces Availability of VEPPANU™ (vepdegestrant) for Patients with ER+/HER2-, ESR1-Mutated Advanced or Metastatic Breast Cancer". Rigel Pharmaceuticals announced that VEPPANU (vepdegestrant) is now available by prescription in the U.S. for adults with ER+/HER2-, ESR1-mutated advanced or metastatic breast cancer whose disease progressed after at least one line of endocrine therapy. The drug is described as the first and only FDA-approved PROTAC.

Company

About Rigel Pharmaceuticals, Inc.

Rigel Pharmaceuticals, Inc. is a biotechnology company focused on discovering, developing, and providing novel therapies that significantly improve the lives of patients with hematologic disorders and cancer. It operates as a clinical-stage biopharmaceutical firm, specializing in targeted drugs within the therapeutic areas of immunology, oncology, and immune oncology. The company's pipeline includes programs targeting IRAK1/4 inhibitors and RIPK1 inhibitors, alongside partnered programs and investigator-sponsored research. Rigel Pharmaceuticals, Inc. emphasizes clinical trials and expanded access policies to advance its product candidates. Its products address unmet needs in hematologic conditions and oncology, positioning it as a key player in specialized biopharma markets serving patients and healthcare providers. Founded in 1996 and headquartered in South San Francisco, California, Rigel Pharmaceuticals, Inc. continues to drive innovation in precision medicine for immune-mediated and cancerous diseases.

CEO Mr. Raul R. Rodriguez · 162 employees · United States · https://www.rigel.com